ストックスクリーナーアプリを入手
9.49
1.74%
-0.09
前日終値:
$9.58
開ける：
$9.61
24時間の取引高:
25,620
Relative Volume:
0.08
時価総額：
$533.87M
収益：
-
当期純損益:
$-72.89M
株価収益率:
-3.8893
EPS:
-2.44
ネットキャッシュフロー:
$-68.47M
1週間 パフォーマンス:
-6.70%
1か月 パフォーマンス:
-16.40%
6か月 パフォーマンス:
+2.32%
1年 パフォーマンス:
+106.89%
1日の値動き範囲:
$9.20
$9.61
1週間の範囲:
$8.61
$10.17
52週間の値動き範囲:
$4.41
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
ATXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ATXS | 9.52 | 533.87M | 0 | -72.89M | -68.47M | -2.44 |
| VRTX | 447.11 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.00 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.63 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.75 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-29 | 開始されました | TD Cowen | Buy |
| 2023-03-28 | 開始されました | Evercore ISI | Outperform |
Astria Therapeutics Inc (ATXS) 最新ニュース
Astria Therapeutics Reports Q3 2024 Financial Results - MSN
Research Analysts Set Expectations for ATXS FY2024 Earnings - MarketBeat
Astria Therapeutics’ (ATXS) Buy Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3%Time to Sell? - MarketBeat
RA Capital Management, L.P. Expands Stake in Astria Therapeutics Inc - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Astria Therapeutics Inc - GuruFocus.com
Oppenheimer Forecasts Strong Price Appreciation for Astria Therapeutics (NASDAQ:ATXS) Stock - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up on Analyst Upgrade - MarketBeat
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth - Simply Wall St
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference - sharewise
FMR LLC Acquires Significant Stake in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Objective long/short (ATXS) Report - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8%Here's What Happened - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema - BioSpace
Astria Therapeutics gains orphan drug status in EU for HAE treatment - Investing.com Australia
(ATXS) Trading Report - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Down 9.2% in September - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1%Should You Sell? - MarketBeat
Renaissance Technologies LLC Decreases Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Dimensional Fund Advisors LP Buys 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Cubist Systematic Strategies LLC Purchases New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Trading 5.2% HigherHere's What Happened - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Millennium Management LLC - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by Analysts - MarketBeat
Insider Sale Alert: Astria Therapeutics Inc [ATXS] – Is it Time to sell? - Knox Daily
Nantahala Capital Management LLC Makes New $6.14 Million Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Are Astria Therapeutics Inc (ATXS) shares a good deal now? - US Post News
Closing Figures Unveiled: Astria Therapeutics Inc (ATXS) Drop -1.17, Closes at 11.01 - The Dwinnex
Logos Global Management LP Decreases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema - StockTitan
Cubist Systematic Strategies LLC Invests $2.56 Million in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Driehaus Capital Management LLC Sells 15,057 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Earns Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics to Present at Upcoming Global Angioedema Forum - StockTitan
Financial Snapshot: Analyzing Astria Therapeutics Inc (ATXS)’s Key Ratio Metrics - The Dwinnex
ATXS’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Astria Therapeutics Inc (ATXS) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):